Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 6, 2020
Daily News
August 6, 2020
- Torii Gets Japan Option Rights to Verrica’s Warts Drug
August 6, 2020
- MSD Japan Chief Wants Talks with Govt, Re-Pricing Rules Revisited to Help Innovation Thrive
August 6, 2020
- Tsutomu Iuchi to Lead MHLW's Medical Economics Division
August 6, 2020
- SymBio to Tap Into Global Development of Brincidofovir IV for Post-HSTC Adenovirus Infection
August 6, 2020
- Takara Bio to End License Deal for Oncolytic Viral Immunotherapy with Chinese Firm
August 6, 2020
- Sumitomo Dainippon, Save Medical Link Up on Diabetes App; Approval Eyed in FY2022
August 6, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…